163P Population-adjusted comparison of SOLAR-1 and BOLERO-2: PFS with second-line alpelisib + fulvestrant vs everolimus + exemestane in postmenopausal pts with PIK3CA-mut hormone-receptor positive (HR+) human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC)